
Brenda Libby Coleman
Examiner (ID: 13884, Phone: (571)272-0665 , Office: P/1624 )
| Most Active Art Unit | 1624 |
| Art Unit(s) | 1202, 2611, 1624, 1611 |
| Total Applications | 3154 |
| Issued Applications | 1967 |
| Pending Applications | 488 |
| Abandoned Applications | 741 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18444491
[patent_doc_number] => 11680049
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-06-20
[patent_title] => Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/946024
[patent_app_country] => US
[patent_app_date] => 2022-09-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 26373
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17946024
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/946024 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | Sep 14, 2022 | Issued |
Array
(
[id] => 18162134
[patent_doc_number] => 20230028726
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-26
[patent_title] => CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/942121
[patent_app_country] => US
[patent_app_date] => 2022-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26316
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17942121
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/942121 | Certain (2S)-N-[(1 s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | Sep 9, 2022 | Issued |
Array
(
[id] => 18384456
[patent_doc_number] => 11655224
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-05-23
[patent_title] => Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/942122
[patent_app_country] => US
[patent_app_date] => 2022-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 26379
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 143
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17942122
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/942122 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | Sep 9, 2022 | Issued |
Array
(
[id] => 18166967
[patent_doc_number] => 20230033573
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-02
[patent_title] => CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/942123
[patent_app_country] => US
[patent_app_date] => 2022-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26555
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17942123
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/942123 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | Sep 9, 2022 | Issued |
Array
(
[id] => 18384454
[patent_doc_number] => 11655222
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-05-23
[patent_title] => Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/942120
[patent_app_country] => US
[patent_app_date] => 2022-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 26370
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 136
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17942120
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/942120 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | Sep 9, 2022 | Issued |
Array
(
[id] => 18428661
[patent_doc_number] => 11673871
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-06-13
[patent_title] => Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/942112
[patent_app_country] => US
[patent_app_date] => 2022-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 26358
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 144
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17942112
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/942112 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | Sep 9, 2022 | Issued |
Array
(
[id] => 18384453
[patent_doc_number] => 11655221
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-05-23
[patent_title] => Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/942106
[patent_app_country] => US
[patent_app_date] => 2022-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 26386
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 117
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17942106
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/942106 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | Sep 8, 2022 | Issued |
Array
(
[id] => 18612237
[patent_doc_number] => 20230278969
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/942111
[patent_app_country] => US
[patent_app_date] => 2022-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26606
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17942111
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/942111 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | Sep 8, 2022 | Issued |
Array
(
[id] => 18375912
[patent_doc_number] => 20230150993
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => ANTIPROLIFERATION COMPOUNDS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/930352
[patent_app_country] => US
[patent_app_date] => 2022-09-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 99001
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930352
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/930352 | Antiproliferation compounds and uses thereof | Sep 6, 2022 | Issued |
Array
(
[id] => 19504943
[patent_doc_number] => 12116354
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-15
[patent_title] => RIP1 inhibitory compounds and methods for making and using the same
[patent_app_type] => utility
[patent_app_number] => 17/939020
[patent_app_country] => US
[patent_app_date] => 2022-09-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28710
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 271
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17939020
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/939020 | RIP1 inhibitory compounds and methods for making and using the same | Sep 6, 2022 | Issued |
Array
(
[id] => 19274391
[patent_doc_number] => 12024502
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-02
[patent_title] => Biased adrenergic agonists
[patent_app_type] => utility
[patent_app_number] => 17/902085
[patent_app_country] => US
[patent_app_date] => 2022-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 29
[patent_no_of_words] => 12268
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17902085
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/902085 | Biased adrenergic agonists | Sep 1, 2022 | Issued |
Array
(
[id] => 18420007
[patent_doc_number] => 20230174468
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => SULFATED PILLARARENES, METHODS OF MAKING SAME, AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/822863
[patent_app_country] => US
[patent_app_date] => 2022-08-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27731
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17822863
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/822863 | SULFATED PILLARARENES, METHODS OF MAKING SAME, AND USES THEREOF | Aug 28, 2022 | Pending |
Array
(
[id] => 18886355
[patent_doc_number] => 11865111
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-09
[patent_title] => Antiviral drugs targeting the N-terminal domain (NTD) of the coronavirus spike receptor binding domain (RBD)
[patent_app_type] => utility
[patent_app_number] => 17/819178
[patent_app_country] => US
[patent_app_date] => 2022-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 2752
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17819178
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/819178 | Antiviral drugs targeting the N-terminal domain (NTD) of the coronavirus spike receptor binding domain (RBD) | Aug 10, 2022 | Issued |
Array
(
[id] => 18208197
[patent_doc_number] => 20230054455
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => CONTROLLED RELEASE FORMULATIONS OF RILUZOLE AND THEIR USES
[patent_app_type] => utility
[patent_app_number] => 17/882707
[patent_app_country] => US
[patent_app_date] => 2022-08-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18411
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17882707
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/882707 | Controlled release formulations of riluzole and their uses | Aug 7, 2022 | Issued |
Array
(
[id] => 18909249
[patent_doc_number] => 11872212
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-16
[patent_title] => Self-healing organic crystals
[patent_app_type] => utility
[patent_app_number] => 17/873246
[patent_app_country] => US
[patent_app_date] => 2022-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 5418
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 97
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17873246
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/873246 | Self-healing organic crystals | Jul 25, 2022 | Issued |
Array
(
[id] => 18229130
[patent_doc_number] => 20230068124
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => Hydrazinyl-Indole Compounds and Methods for Producing a Conjugate
[patent_app_type] => utility
[patent_app_number] => 17/874122
[patent_app_country] => US
[patent_app_date] => 2022-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49811
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17874122
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/874122 | Hydrazinyl-Indole Compounds and Methods for Producing a Conjugate | Jul 25, 2022 | Abandoned |
Array
(
[id] => 18391337
[patent_doc_number] => 20230159555
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS
[patent_app_type] => utility
[patent_app_number] => 17/814115
[patent_app_country] => US
[patent_app_date] => 2022-07-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 189590
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17814115
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/814115 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | Jul 20, 2022 | Pending |
Array
(
[id] => 18420036
[patent_doc_number] => 20230174497
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => RHEIN AMIDE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF, AND INHIBITOR OF HEPATOCELLULAR CARCINOMA (HCC) WITH SPECIFIC RECQL4 EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 17/811201
[patent_app_country] => US
[patent_app_date] => 2022-07-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5861
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17811201
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/811201 | RHEIN AMIDE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF, AND INHIBITOR OF HEPATOCELLULAR CARCINOMA (HCC) WITH SPECIFIC RECQL4 EXPRESSION | Jul 6, 2022 | Abandoned |
Array
(
[id] => 18272007
[patent_doc_number] => 20230093249
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-23
[patent_title] => ANTI-VIRAL COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/811008
[patent_app_country] => US
[patent_app_date] => 2022-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 104094
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -62
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17811008
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/811008 | Anti-viral compounds | Jul 5, 2022 | Issued |
Array
(
[id] => 19290402
[patent_doc_number] => 12029741
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-07-09
[patent_title] => 5 beta dihydrotestosterone pharmaceutical formulations and related methods
[patent_app_type] => utility
[patent_app_number] => 17/853497
[patent_app_country] => US
[patent_app_date] => 2022-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 19589
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17853497
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/853497 | 5 beta dihydrotestosterone pharmaceutical formulations and related methods | Jun 28, 2022 | Issued |